Structure based discovery of small molecules to regulate the activity of human insulin degrading enzyme.

<h4>Background</h4>Insulin-degrading enzyme (IDE) is an allosteric Zn(+2) metalloprotease involved in the degradation of many peptides including amyloid-β, and insulin that play key roles in Alzheimer's disease (AD) and type 2 diabetes mellitus (T2DM), respectively. Therefore, the u...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Bilal Çakir, Onur Dağliyan, Ezgi Dağyildiz, İbrahim Bariş, Ibrahim Halil Kavakli, Seda Kizilel, Metin Türkay
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2012
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/3dd7ae4f82a24c09a82745dfaee9413e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3dd7ae4f82a24c09a82745dfaee9413e
record_format	dspace
spelling	oai:doaj.org-article:3dd7ae4f82a24c09a82745dfaee9413e2021-11-18T07:28:08ZStructure based discovery of small molecules to regulate the activity of human insulin degrading enzyme.1932-620310.1371/journal.pone.0031787https://doaj.org/article/3dd7ae4f82a24c09a82745dfaee9413e2012-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22355395/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>Insulin-degrading enzyme (IDE) is an allosteric Zn(+2) metalloprotease involved in the degradation of many peptides including amyloid-β, and insulin that play key roles in Alzheimer's disease (AD) and type 2 diabetes mellitus (T2DM), respectively. Therefore, the use of therapeutic agents that regulate the activity of IDE would be a viable approach towards generating pharmaceutical treatments for these diseases. Crystal structure of IDE revealed that N-terminal has an exosite which is ∼30 Å away from the catalytic region and serves as a regulation site by orientation of the substrates of IDE to the catalytic site. It is possible to find small molecules that bind to the exosite of IDE and enhance its proteolytic activity towards different substrates.<h4>Methodology/principal findings</h4>In this study, we applied structure based drug design method combined with experimental methods to discover four novel molecules that enhance the activity of human IDE. The novel compounds, designated as D3, D4, D6, and D10 enhanced IDE mediated proteolysis of substrate V, insulin and amyloid-β, while enhanced degradation profiles were obtained towards substrate V and insulin in the presence of D10 only.<h4>Conclusion/significance</h4>This paper describes the first examples of a computer-aided discovery of IDE regulators, showing that in vitro and in vivo activation of this important enzyme with small molecules is possible.Bilal ÇakirOnur DağliyanEzgi Dağyildizİbrahim BarişIbrahim Halil KavakliSeda KizilelMetin TürkayPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 7, Iss 2, p e31787 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Bilal Çakir Onur Dağliyan Ezgi Dağyildiz İbrahim Bariş Ibrahim Halil Kavakli Seda Kizilel Metin Türkay Structure based discovery of small molecules to regulate the activity of human insulin degrading enzyme.
description	<h4>Background</h4>Insulin-degrading enzyme (IDE) is an allosteric Zn(+2) metalloprotease involved in the degradation of many peptides including amyloid-β, and insulin that play key roles in Alzheimer's disease (AD) and type 2 diabetes mellitus (T2DM), respectively. Therefore, the use of therapeutic agents that regulate the activity of IDE would be a viable approach towards generating pharmaceutical treatments for these diseases. Crystal structure of IDE revealed that N-terminal has an exosite which is ∼30 Å away from the catalytic region and serves as a regulation site by orientation of the substrates of IDE to the catalytic site. It is possible to find small molecules that bind to the exosite of IDE and enhance its proteolytic activity towards different substrates.<h4>Methodology/principal findings</h4>In this study, we applied structure based drug design method combined with experimental methods to discover four novel molecules that enhance the activity of human IDE. The novel compounds, designated as D3, D4, D6, and D10 enhanced IDE mediated proteolysis of substrate V, insulin and amyloid-β, while enhanced degradation profiles were obtained towards substrate V and insulin in the presence of D10 only.<h4>Conclusion/significance</h4>This paper describes the first examples of a computer-aided discovery of IDE regulators, showing that in vitro and in vivo activation of this important enzyme with small molecules is possible.
format	article
author	Bilal Çakir Onur Dağliyan Ezgi Dağyildiz İbrahim Bariş Ibrahim Halil Kavakli Seda Kizilel Metin Türkay
author_facet	Bilal Çakir Onur Dağliyan Ezgi Dağyildiz İbrahim Bariş Ibrahim Halil Kavakli Seda Kizilel Metin Türkay
author_sort	Bilal Çakir
title	Structure based discovery of small molecules to regulate the activity of human insulin degrading enzyme.
title_short	Structure based discovery of small molecules to regulate the activity of human insulin degrading enzyme.
title_full	Structure based discovery of small molecules to regulate the activity of human insulin degrading enzyme.
title_fullStr	Structure based discovery of small molecules to regulate the activity of human insulin degrading enzyme.
title_full_unstemmed	Structure based discovery of small molecules to regulate the activity of human insulin degrading enzyme.
title_sort	structure based discovery of small molecules to regulate the activity of human insulin degrading enzyme.
publisher	Public Library of Science (PLoS)
publishDate	2012
url	https://doaj.org/article/3dd7ae4f82a24c09a82745dfaee9413e
work_keys_str_mv	AT bilalcakir structurebaseddiscoveryofsmallmoleculestoregulatetheactivityofhumaninsulindegradingenzyme AT onurdagliyan structurebaseddiscoveryofsmallmoleculestoregulatetheactivityofhumaninsulindegradingenzyme AT ezgidagyildiz structurebaseddiscoveryofsmallmoleculestoregulatetheactivityofhumaninsulindegradingenzyme AT ibrahimbaris structurebaseddiscoveryofsmallmoleculestoregulatetheactivityofhumaninsulindegradingenzyme AT ibrahimhalilkavakli structurebaseddiscoveryofsmallmoleculestoregulatetheactivityofhumaninsulindegradingenzyme AT sedakizilel structurebaseddiscoveryofsmallmoleculestoregulatetheactivityofhumaninsulindegradingenzyme AT metinturkay structurebaseddiscoveryofsmallmoleculestoregulatetheactivityofhumaninsulindegradingenzyme
_version_	1718423403448238080

Structure based discovery of small molecules to regulate the activity of human insulin degrading enzyme.

Ejemplares similares